Carmignac Gestion’s Regenxbio RGNX Stock Holding History

Carmignac Gestion’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Hold	–	-$10M	–	135
2021 Q2	–	Hold	–	–	–	72
2021 Q1	–	Hold	–	-$7.56M	–	155
2020 Q4	–	Hold	–	–	–	71

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Carmignac Gestion's RGNX Position: Q1 2022 in Review

Carmignac Gestion sold out of Regenxbio (RGNX) in Q1 2022, closing a stake of 46,369 shares — an estimated $1.52M sold.

Carmignac Gestion first reported a position in RGNX in Q2 2018 and held it in 15 quarters. The position peaked at $71M in Q2 2019. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2022.

Carmignac Gestion reported no remaining Regenxbio position as of Q1 2022 after selling out during the quarter.
Carmignac Gestion sold 46,369 Regenxbio shares in Q1 2022, an estimated $1.52M.
Carmignac Gestion first reported a position in Regenxbio in Q2 2018 and held it in 15 quarters.
Carmignac Gestion's Regenxbio position peaked at $71M in Q2 2019.
188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2022.

Based on Carmignac Gestion's 13F filing for Q1 2022, filed 13 May 2022.